Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase II study evaluating the activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory Cancers of childhood
Protocol ID
RG_16-040 (PARC)
Disease (Sub Disease)
All Tumour Types (Other)
Diagnosis Stage
Relapse/ refractory
Location
NSW, QLD, VIC, WA, SA
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
University of Birmingham
Trial Status
Open
Sites
The Children's Hospital at Westmead
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Royal Children's Hospital
Women's & Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
1 year to 25 years
International registry ID's
NCT03455140
Back to Registry
Study Title A Phase II study evaluating the activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory Cancers of childhood
Protocol ID RG_16-040 (PARC)
Disease (Sub Disease) All Tumour Types (Other)
Diagnosis Stage Relapse/ refractory
Location NSW / QLD / VIC / WA / SA
Sponsor Australian and New Zealand Children's Haematology Oncology Group/ University of Birmingham
Links https://clinicaltrials.gov/ct2/show/NCT03455140
Trial Status Open
Trial Open Date 29/11/2019
Sites The Children's Hospital at Westmead / Perth Children's Hospital / Queensland Children's Hospital / Sydney Children's Hospital / Royal Children's Hospital / Women's & Children's Hospital
Study Type Treatment
Phase Phase 1/2
Age Eligibility 1 year to 25 years
International registry ID's NCT03455140